Risk-Stratified Hypofractionated Radiotherapy After Breast-Conserving Surgery for Early Breast Cancer
A Prospective Study of Risk-Stratified Hypofractionated Radiotherapy After Breast-Conserving Surgery for Early Breast Cancer
研究概览
地位
详细说明
Eligible patients with early breast cancer who have undergone breast-conserving surgery will be stratified into a high-risk group or a low-risk group according to the presence or absence of predefined high-risk factors.
Patients in the high-risk group will receive whole-breast irradiation with a simultaneous integrated boost to the tumor bed. The prescribed dose will be 36 Gy in 15 fractions over 3 weeks to the whole breast and 48 Gy in 15 fractions over 3 weeks to the tumor bed.
Patients in the low-risk group will receive partial-breast irradiation. Two hypofractionated schedules may be used: 40.05 Gy in 15 fractions over 3 weeks or 26 Gy in 5 fractions over 1 week.
Patients will be followed during and after radiotherapy to evaluate treatment efficacy, recurrence rates, and acute and late radiation-related toxicities.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Shu-Lian Wang, MD
- 电话号码:8610-87788803
- 邮箱:wangsl@cicams.ac.cn
学习地点
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100021
- Cancer Hospital, Chinese Academy of Medical Sciences
-
接触:
- Shu-Lian Wang
- 电话号码:8610-87788803
- 邮箱:wangsl@cicams.ac.cn
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- ECOG performance status score of 0 to 2.
- Pathologically confirmed breast cancer, including invasive carcinoma or ductal carcinoma in situ.
- Clinical stage cT0-2N0M0.
- Underwent breast-conserving surgery.
- Negative surgical margins greater than 2 mm.
Exclusion Criteria:
- Regional lymph node metastasis.
- Distant metastasis.
- Bilateral breast cancer.
- Prior thoracic radiotherapy.
- Life expectancy of less than 5 years.
- Lactating or pregnant women.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:阶乘赋值
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Arm 1: High-risk group
Patients who undergo upfront breast-conserving surgery will be assigned to the high-risk group if any of the following high-risk factors are present:
Patients who receive neoadjuvant chemotherapy followed by breast-conserving surgery will be assigned to the high-risk group if any of the following high-risk factors are present:
|
Whole-breast irradiation: 36 Gy in 15 fractions; Tumor bed boost: 48 Gy in 15 fractions
|
|
有源比较器:Arm 2: Low-risk group
Patients who undergo upfront breast-conserving surgery will be assigned to the low-risk group if they meet either of the following criteria: ① Ductal carcinoma in situ (DCIS): age 40 years or older, unifocal disease on breast MRI, tumor size 3 cm or smaller, estrogen receptor-positive disease, and low-, intermediate-, or high-grade disease. ② Invasive carcinoma, including invasive ductal carcinoma, mucinous carcinoma, papillary carcinoma, or tubular carcinoma: age 40 years or older, unifocal disease on breast MRI, tumor size 3 cm or smaller, grade 1 to 3 disease, no lymphovascular invasion, and estrogen receptor-positive disease. Patients who receive neoadjuvant chemotherapy followed by breast-conserving surgery will be assigned to the low-risk group if all of the following criteria are met: Age 40 years or older, unifocal disease on pretreatment breast MRI, pretreatment core needle biopsy showing invasive ductal carcinoma, and pathologic stage ypT0/isN0. |
Partial-breast irradiation: 40.05 Gy in 15 fractions or 26 Gy in 5 fractions
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Local recurrence rate
大体时间:Five years
|
Ipsilateral breast recurrence rate
|
Five years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Disease-free survival rate
大体时间:Five years
|
Disease-free survival rate
|
Five years
|
|
Radiation-related adverse events
大体时间:Five years
|
Adverse events
|
Five years
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.